Raytheon awarded $71 million in Navy contracts for missile systems
PURCHASE, N.Y. - Cognition Therapeutics, Inc. (NASDAQ:CGTX) has regained compliance with Nasdaq’s continued listing requirements after meeting the minimum share price threshold, the clinical-stage neurodegenerative disease drug developer announced Tuesday. The stock has demonstrated remarkable momentum, surging over 90% in the past week and trading at $2.85, according to InvestingPro data.
The company received notification from Nasdaq Listing Qualifications Staff that it had satisfied the exchange’s Rule 5550(a)(2), known as the Bid Price Rule, which requires maintaining a minimum closing bid price of $1.00 or more for at least 10 consecutive business days.
Cognition Therapeutics met this requirement on Monday, August 25, 2025, allowing Nasdaq to close the bid price deficiency matter.
The company is currently developing zervimesine (CT1812), its lead candidate, which has completed Phase 2 studies for dementia with Lewy bodies, mild-to-moderate Alzheimer’s disease, and geographic atrophy secondary to dry AMD. Additionally, an ongoing Phase 2 START study in early Alzheimer’s disease is supported by $81 million in grant funding from the National Institute of Aging.
According to the press release statement, zervimesine works by regulating impaired pathways through interaction with the sigma-2 receptor, a mechanism the company describes as functionally distinct from other approaches to treating degenerative diseases. Analysts maintain a bullish outlook on CGTX, with price targets ranging from $2 to $4, as revealed in InvestingPro’s detailed research report, which includes 13 additional key insights about the company’s performance and prospects.
In other recent news, Cognition Therapeutics, Inc. has made significant strides in its Alzheimer’s disease drug development. The company received confirmation from the FDA that its proposed Phase 3 program design for the drug candidate zervimesine (CT1812) could support a New Drug Application. This decision follows the company’s end-of-Phase 2 meeting with the FDA, which endorsed plans to enroll adults with mild-to-moderate Alzheimer’s disease who have lower levels of p-tau217 at screening. Additionally, Cognition Therapeutics published promising results from its Phase 2 SEQUEL study of zervimesine, highlighting positive effects on brain activity. These findings were detailed in the journal Alzheimer’s & Dementia: Translational Research & Clinical Interventions. Furthermore, the company announced upcoming presentations of Phase 2 study results for its dementia with Lewy bodies treatment, which have already spurred interest and excitement. Dr. James E. Galvin, associated with the University of Miami Miller School of Medicine, will present these findings at the Alzheimer’s Association International Conference. These developments reflect Cognition Therapeutics’ ongoing progress in neurodegenerative disease research.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.